Leah Kuntz

Tris Pharma's TRN-257, a low-sodium oxybate, offers a once-nightly treatment option for narcolepsy and idiopathic hypersomnia, enhancing patient care.

Teva Pharmaceuticals has submitted an NDA to the FDA for extended-release injectable olanzapine for the treatment of schizophrenia.

Newron Pharmaceuticals launches a pivotal study on evenamide, targeting treatment-resistant schizophrenia to improve patient outcomes and address unmet needs.

What were the top psychiatric hits of 2025?

Incannex Healthcare's PSX-001 shows promise in treating generalized anxiety disorder, offering innovative, effective solutions beyond traditional therapies.

A critical shortage of IV lorazepam disrupts psychiatric care, particularly for patients with catatonia, highlighting broader pharmaceutical supply chain issues.

Bristol Myers Squibb expands patient enrollment in the ADEPT-2 study, exploring Cobenfy's potential for treating Alzheimer disease-related psychosis.

Explore impactful ways to contribute on Giving Tuesday, supporting mental health organizations dedicated to making a difference in psychiatry.

What are the most important psychiatric advancements and insights from 2025? Share with us!

Check out the pipeline updates from November!

Discover the latest insights from Southern Florida Psychiatry Conference on stuttering, its neurological basis, and innovative treatment approaches to improve quality of life for those affected.

Vagus nerve stimulation offers a promising solution for treatment-resistant depression, showcasing significant long-term efficacy and durability in patients.

Experts at the Southern Florida Psychiatry Conference emphasize the importance of screening for postpartum depression, highlighting effective treatments and support strategies for new mothers' mental health.

Digital therapeutics revolutionize health care by enhancing patient outcomes through technology and offering scalable, evidence-based treatments for various conditions.

Silo Pharma partners with Allucent to advance SPC-15, a novel treatment for PTSD, aiming for FDA approval and addressing unmet patient needs.

FDA expands Deep TMS therapy for adolescents with major depressive disorder, offering a noninvasive treatment option for underserved youth.

EXCLUSIVE: Check out this recap on the approval of lumateperone (Caplyta) for major depressive disorder.

Alixorexton shows promising results in improving wakefulness and reducing daytime sleepiness in patients with narcolepsy type 2.

Caplyta, now FDA-approved as an adjunctive therapy for major depressive disorder, offers rapid relief and a favorable safety profile for patients. Learn more from Suresh Durgam, MD, the primary investigator.

Neurocrine's NBI-1070770 fails to meet primary endpoint in phase 2 trial for major depressive disorder, prompting further analysis of results.

New research reveals hyperbaric oxygen therapy as a promising treatment for chronic PTSD, enhancing brain function and providing lasting symptom relief.

AtaiBeckley reveals promising phase 2b open-label extension study results for BPL-003, showing sustained antidepressant effects in patients with treatment-resistant depression after redosing.

Johnson & Johnson's Caplyta gains FDA approval as an adjunctive treatment for major depressive disorder, offering hope for improved patient outcomes.

Axsome Therapeutics advances AXS-05 for Alzheimer disease agitation, showing significant improvement in clinical trials and addressing critical patient needs.

Share your innovative best practices that enhance patient care!

Halloween poses unique challenges for individuals with mental health disorders, but strategies exist to help them navigate the spooky season safely.

Check out the pipeline updates from October!

Cingulate's CTx-1301 shows promising phase 3 results for ADHD, offering effective once-daily dosing and potential FDA approval by 2026.

Laguna Diagnostics revolutionizes psychiatric interventions with patented blood tests that accurately diagnose schizophrenia and bipolar disorder.